Swedish Orphan Biovitrum AB (Sobi) and Auxilium Pharmaceuticals, Inc. have announced that Sobi has filed for an extension of the...
The National Institute for Health and Care Excellence (NICE) has in draft guidance recommended Xiapex (clostridial collagenase for injection) for...
Swedish Orphan Biovitrium (Sobi) announced that the EU Commission has approved Xiapex (collagenase clostridium histolyticum) for the treatment of adult...
On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation...
Auxilium Pharmaceuticals, and Swedish Orphan Biovitrum AB (SOBI) have entered into a long-term collaboration for the development, supply and commercialization...
Actelion will acquire from Auxilium Pharma exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare...
Auxilium Pharmaceuticals and Swedish Orphan Biovitrum AB announced that data were presented from multiple clinical trials evaluating the use of...
Data from multiple trials evaluating the use of Xiaflex/Xiapex (collagenase clostridium histolyticum), from Auxilium Pharma and SOBI, in adult patients...
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life...
The primary objective of this study is to assess the safety of two concurrent injections of AA4500 into the same...